Renal Denervation Hypertension After Stroke

Pilot Study in Renal Denervation in Patients With Stroke and Uncontrolled Hypertension

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01689415

Acronym

REHEARSE

Enrollment

Registered

2012-09-21

Start date

2012-09-30

Completion date

2014-11-30

Last updated

2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Stroke

Keywords

Renal nerve denervation

Brief summary

It is known, that hypertension is the major risk factor of stroke and recurrent stroke. Blood pressure reduction - together with antithrombotics - remain crucial in stroke prevention. This pilot study will examine the effect of renal nerve denervation in patients with treatment resistant hypertension after ischemic stroke or DWI/DTI-verified stroke. With 24 hours blood pressure measurements the effect after renal nerve denervation is examined 1,3,6 and 12 months after the procedure.

Detailed description

Radio frequent ablation is used to renal nerve denervation (RND) and is a new invasive method used in treatment for hypertensive patients, where the sympathetic nerves to the kidneys ablates. RND shows a significant reduction in the systolic and diastolic blood pressure in patients with treatment resistant hypertension. The hypothesis is that RDN is able to reduce the blood pressure in patients with previous stroke and treatment resistant hypertension and thereby reduce the risk of a new stroke. Aim of study: 1. To validate the reduction in blood pressure after RND in patients with stroke and treatment resistant hypertension compared to the results achieved in patients only with essential hypertension 2. To examine if this treatment is possible on patients after stroke (procedure related limitations and security of the patient) 3. To describe the effect of RND in the development of changes in the white matter over time

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18+ years old * Clinical verified stroke within the last year * Treatment resistant hypertension at 150 mm Hg or higher systolic at consultation * Modified Ranking between 0-2

Exclusion criteria

* Lack of informed consent * Renal artery anatomy, which prevents the procedure * Reno vascular disease * Pacemaker * Haemodynamic vascular occlusion or valve disease * Pregnancy or women in the childbearing age * Secondary hypertension * Mean systolic blood pressure over 180 mm Hg

Design outcomes

Primary

Measure	Time frame
24 hour blood pressure	3 months

Countries

Denmark

Outcome results